Allergic Rhinitis


Algorithm and Annotations for Diagnosis and Management of Rhinitis, Ann Allergy Asthma Immunol, 1998;81:469–73.


18. Dykewicz MS, Fineman S, Skoner DP, et al., Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology, Ann Allergy Asthma Immunol, 1998;81:478–518.


19. Devenny A, Wassall H, Ninan T, et al., Respiratory symptoms and atopy in children in Aberdeen: questionnaire studies of a defined school population repeated over 35 years, BMJ, 2004;329:489–90.


20. Nicolai T, Bellach B, Mutius EV, et al., Increased prevalence of sensitization against aeroallergens in adults in West compared with East Germany, Clin Exp Allergy, 1997;27:886–92.


21. Ninan TK, Russell G, Respiratory symptoms and atopy in Aberdeen schoolchildren: evidence from two surveys 25 years apart, BMJ, 1992;304:873–5.


22. Strachan D, Sibbald B, Weiland S, et al., Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC), Pediatr Allergy Immunol, 1997;8:161–76.


23. Bousquet J, Van Cauwenberge P, Khaltaev N, Allergic rhinitis and its impact on asthma, J Allergy Clin Immunol, 2001;108(5 Suppl.):S147–334.


24. Wang DY, Risk factors of allergic rhinitis: genetic or environmental?, Ther Clin Risk Manag, 2005;1:115–23.


25. Bodner C, Godden D, Seaton A, Family size, childhood infections and atopic diseases. The Aberdeen WHEASE Group, Thorax, 1998;53:28–32.


26. Kramer U, Heinrich J, Wjst M, et al., Age of entry to day nursery and allergy in later childhood, Lancet, 1999;353:450–4.


27. Marshall PS, O'Hara C, Steinberg P, Effects of seasonal allergic rhinitis on fatigue levels and mood, Psychosom Med, 2002;64:684–91.


28. Strachan DP, Hay fever, hygiene, and household size, BMJ, 1989;299:1259–60.


29. von Mutius E, Allergies, infections and the hygiene hypothesis-- the epidemiological evidence, Immunobiology, 2007;212:433–9.


30. Illi S, von Mutius E, Lau S, et al., Early childhood infectious diseases and the development of asthma up to school age: a birth cohort study, BMJ, 2001;322:390–5.


31. Matheson MC, Walters EH, Simpson JA, et al., Relevance of the hygiene hypothesis to early vs. late onset allergic rhinitis, Clin Exp Allergy, 2009;39:370–8.


32. Church MK, Maurer M, Simons FE, et al., Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper, Allergy, 2010;65:459–66.


33. Mansfield LE, Diaz G, Posey CR, et al., Sleep disordered breathing and daytime quality of life in children with allergic rhinitis during treatment with intranasal budesonide, Ann Allergy Asthma Immunol, 2004;92:240–4.


34. Storms W, Allergic rhinitis-induced nasal congestion: its impact on sleep quality, Prim Care Respir J, 2008;17:7–18.


35. Young T, Blustein J, Finn L, et al., Sleep-disordered breathing and motor vehicle accidents in a population-based sample of employed adults, Sleep, 1997;20:608–13.


36. Young T, Finn L, Kim H, Nasal obstruction as a risk factor for sleep-disordered breathing. The University of Wisconsin Sleep and Respiratory Research Group, J Allergy Clin Immunol, 1997;99:S757–62.


37. Nasr S, Altman EG, Meltzer HY, Concordance of atopic and affective disorders, J Affect Disord, 1981;3:291–6.


38. Postolache TT, Komarow H, Tonelli LH, Allergy: a risk factor for suicide?, Curr Treat Options Neurol, 2008;10:363–76.


39. Sugerman AA, Southern DL, Curran JF, A study of antibody levels in alcoholic, depressive and schizophrenic patients, Ann Allergy, 1982;48:166–71.


40. Cohen P, Pine DS, Must A, et al., Prospective associations between somatic illness and mental illness from childhood to adulthood, Am J Epidemiol, 1998;147:232–9.


41. Hurwitz EL, Morgenstern H, Cross-sectional associations of asthma, hay fever, and other allergies with major depression and low-back pain among adults aged 20-39 years in the United States, Am J Epidemiol, 1999;150:1107–16.


42. Bousquet J, Khaltaev N, Cruz AA, et al., Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen), Allergy, 2008;63(Suppl. 86):8–160.


43. Bousquet J, Reid J, van Weel C, et al., Allergic rhinitis management pocket reference 2008, Allergy, 2008;63:990–6.


44. Evans R 3rd, Mullally DI, Wilson RW, et al., National trends in the morbidity and mortality of asthma in the US. Prevalence, hospitalization and death from asthma over two decades: 1965- 1984, Chest, 1987;91(6 Suppl.):65S–74S.


45. Nayak AS, The asthma and allergic rhinitis link, Allergy Asthma Proc, 2003;24:395–402.


46. Spector SL, Overview of comorbid associations of allergic rhinitis, J Allergy Clin Immunol, 1997;99:S773–80.


47. Gaugris S, Sazonov-Kocevar V, Thomas M, Burden of concomitant allergic rhinitis in adults with asthma, J Asthma, 2006;43:1–7.


48. Leynaert B, Neukirch F, Demoly P, et al., Epidemiologic evidence for asthma and rhinitis comorbidity, J Allergy Clin Immunol, 2000;106(5 Suppl.):S201–5.


49. Pawankar R, Allergic rhinitis and asthma: are they manifestations of one syndrome?, Clin Exp Allergy, 2006;36:1–4.


50. Settipane RA, Complications of allergic rhinitis, Allergy Asthma Proc, 1999;20:209–13.


51. Braunstahl GJ, Overbeek SE, Kleinjan A, et al., Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways, J Allergy Clin Immunol,


116 2001;107:469–76.


52. Chakir J, Laviolette M, Turcotte H, et al., Cytokine expression in the lower airways of nonasthmatic subjects with allergic rhinitis: influence of natural allergen exposure, J Allergy Clin Immunol, 2000;106:904–10.


53. Baraniuk JN, Neurogenic mechanisms in rhinosinusitis, Curr Allergy Asthma Rep, 2001;1:252–61.


54. Baraniuk JN, Mechanisms of allergic rhinitis, Curr Allergy Asthma Rep, 2001;1:207–17.


55. Crystal-Peters J, Neslusan C, Crown WH, et al., Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma- related hospitalizations and emergency department visits, J Allergy Clin Immunol, 2002;109:57–62.


56. Brozek JL, Bousquet J, Baena-Cagnani CE, et al., Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision, J Allergy Clin Immunol, 2010;126:466–76.


57. Wallace DV, Dykewicz MS, Bernstein DI, et al., The diagnosis and management of rhinitis: an updated practice parameter, J Allergy Clin Immunol, 2008;122(2 Suppl.):S1–84.


58. Cassell HR, Katial RK, Intranasal antihistamines for allergic rhinitis: examining the clinical impact, Allergy Asthma Proc, 2009;30:349–57.


59. Kay GG, Berman B, Mockoviak SH, et al., Initial and steady-state effects of diphenhydramine and loratadine on sedation, cognition, mood, and psychomotor performance, Arch Intern Med, 1997;157:2350–6.


60. Howard ME, Desai AV, Grunstein RR, et al., Sleepiness, sleep-disordered breathing, and accident risk factors in commercial vehicle drivers, Am J Respir Crit Care Med, 2004;170:1014–21.


61. Sen A, Akin A, Craft KJ, et al., First-generation H1 antihistamines found in pilot fatalities of civil aviation accidents, 1990-2005, Aviat Space Environ Med, 2007;78:514–22.


62. Pragst F, Herre S, Bakdash A, Poisonings with diphenhydramine- -a survey of 68 clinical and 55 death cases, Forensic Sci Int, 2006;161:189–97.


63. Scharman EJ, Erdman AR, Wax PM, et al., Diphenhydramine and dimenhydrinate poisoning: an evidence-based consensus guideline for out-of-hospital management, Clin Toxicol (Phila), 2006;44:205–23.


64. Agostini M, Di Marco B, Spinicelli S, et al., IL-2-driven natural killer cell generation: role of anti-H-2b monoclonal antibodies and stromal cells in controlling quantitative and repertoire changes, J Chemother, 2001;13:527–34.


65. McEvoy LK, Smith ME, Fordyce M, et al., Characterizing impaired functional alertness from diphenhydramine in the elderly with performance and neurophysiologic measures, Sleep, 2006;29:957–66.


66. Holgate ST, Broide D, New targets for allergic rhinitis--a disease of civilization, Nat Rev Drug Discov, 2003;2:902–14.


67. Simons FE, Is antihistamine (H1-receptor antagonist) therapy useful in clinical asthma?, Clin Exp Allergy, 1999;29(Suppl. 3):98–104.


68. Andrews LL, Leader WG, An Overview of Second-generation Antihistamines, Louisiana Medicaid Provider Update, 2006;23:28–35.


69. Golightly LK, Greos LS, Second-generation antihistamines: actions and efficacy in the management of allergic disorders, Drugs, 2005;65:341–84.


70. DuBuske LM, Second-generation antihistamines: the risk of ventricular arrhythmias, Clin Ther, 1999;21:281–95.


71. Scadding GK, Richards DH, Price MJ, Patient and physician perspectives on the impact and management of perennial and seasonal allergic rhinitis, Clin Otolaryngol Allied Sci, 2000;25:551–7.


72. Ryan D, Grant-Casey J, Scadding G, et al., Management of allergic rhinitis in UK primary care: baseline audit, Prim Care Respir J, 2005;14:204–9.


73. Angier E, Willington J, Scadding G, et al., Management of allergic and non-allergic rhinitis: a primary care summary of the BSACI guideline, Prim Care Respir J, 2010;19:217–22.


74. Price D, Bond C, Bouchard J, et al., International Primary Care Respiratory Group (IPCRG) Guidelines: management of allergic rhinitis, Prim Care Respir J, 2006;15:58–70.


75. van Cauwenberge P, Van Hoecke H, Vandenbulcke L, et al., Glucocorticosteroids in allergic inflammation: clinical benefits in allergic rhinitis, rhinosinusitis, and otitis media, Immunol Allergy Clin North Am, 2005;25:489–509, vi.


76. Gengo FM, Reduction of the central nervous system adverse effects associated with antihistamines in the management of allergic disorders: strategies and progress, J Allergy Clin Immunol, 1996;98(6 Pt 3):S319–25.


77. Van Cauwenberge P, ARIA: impact of compliance, Clin Exp All Rev, 2005;5:3–6.


78. Van Cauwenberge P, Watelet JB, Van Zele T, et al., Spreading excellence in allergy and asthma: the GA2 LEN (Global Allergy and Asthma European Network) project, Allergy, 2005;60:858–64.


79. Costa DJ, Bousquet PJ, Ryan D, et al., Guidelines for allergic rhinitis need to be used in primary care, Prim Care Respir J, 2009;18:250–7.


80. Allergies in America: A Landmark Survey of Nasal Allergy Sufferers, 2006. Available at:


www.mmcpub.com/scsaia/adult.pdf (accessed 5 April 2011).


81. Meltzer EO, Nathan RA, Derebery J, et al., Physician perceptions of the treatment and management of allergic and nonallergic rhinitis, Allergy Asthma Proc, 2009;30:75–83.


82. Edelstein DR, Aging of the normal nose in adults, Laryngoscope, 1996;106:1–25.


83. Busse PJ, Allergic respiratory disease in the elderly, Am J Med, 2007;120:498–502.


84. Kaliner MA, H1-antihistamines in the elderly, Clin Allergy Immunol, 2002;17:465–81.


85. Passali D, Mosges R, Passali GC, et al., Safety, tolerability and efficacy of sublingual allergoid immunotherapy with three different shortened up-dosing administration schedules, Acta Otorhinolaryngol Ital, 2010;30:131–7.


86. Van Cauwenberge P, Juniper EF, Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis, Clin Exp Allergy, 2000;30:891–9.


87. Dykewicz MS, Fineman S, Executive Summary of Joint Task Force Practice Parameters on Diagnosis and Management of Rhinitis, Ann Allergy Asthma Immunol, 1998;81:463–8.


88. Sheikh A, Khan-Wasti S, Price D, et al., Standardized training for healthcare professionals and its impact on patients with perennial rhinitis: a multi-centre randomized controlled trial, Clin Exp Allergy, 2007;37:90–9.


89. Merlos M, Giral M, Balsa D, et al., Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF), J Pharmacol Exp Ther, 1997;280:114–21.


90. Garcia-Rafanell J, Rupatadine fumarate: antiallergic, histamine and PAF antagonist, Drugs Future, 1996;21:1033–6.


91. Katiyar S, Prakash S, Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis, Prim Care Respir J, 2009;18:57–68.


92. Izquierdo I, Merlos M, Garcia-Rafanell J, Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis, Drugs Today (Barc), 2003;39:451––68.


93. Keam SJ, Plosker GL, Rupatadine: a review of its use in the management of allergic disorders, Drugs, 2007;67:457–74.


94. Kowalski ML, Jurkiewicz D, Kruszewski J, Rupatadine 10 and 20 mg are effective and safe in the treatment of perennial allergic rhinitis after 4 weeks of treatment: a randomized, double-blind, controlled trial with loratadine and placebo, Therapy, 2009;6:417–25.


95. Molina M, Pinto E, Cistero A, et al., Rupatadine 10 mg in adolescent and adult symptom relief of perennial allergic rhinitis, Therapy, 2010;7:429–36.


96. Saint-Martin F, Dumur JP, Perez I, et al., A randomized, double- blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis, J Investig Allergol Clin Immunol, 2004;14:34–40.


97. Ciprandi G, Cirillo I, Rupatadine improves nasal symptoms, airflow and inflammation in patients with persistent allergic rhinitis: a pilot study, J Biol Regul Homeost Agents, 2010;24:177–83.


98. Izquierdo I, Cranswick N, McCreanor J, et al., Rupatadine oral solution in children aged 6-11 years with allergic rhinitis: a proof of concept evaluation by a 4 weeks treatment follow-up study, Pediatr Allergy Immunol, 2009;20:2.


99. Stuebner P, Horak F, Zieglmayer R, et al., Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber, Ann Allergy Asthma Immunol, 2006;96:37–44.


100. Vuurman E, Theunissen E, van Oers A, et al., Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers, Hum Psychopharmacol, 2007;22:289–97.


101. Donado E, Izquierdo I, Perez I, et al., No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines, Br J Clin Pharmacol, 2010;69:401–10.


102. Martinez-Cocera C, De Molina M, Marti-Guadano E, et al., Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study, J Investig Allergol Clin Immunol, 2005;15:22–9.


103. Fantin S, Maspero J, Bisbal C, et al., A 12-week placebo- controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis, Allergy, 2008;63:924–31.


104. Bachert C, Bousquet J, Canonica GW, et al., Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis, J Allergy Clin Immunol, 2004;114:838–44.


105. Ciprandi G, Cirillo I, Vizzaccaro A, et al., Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study, Clin Exp Allergy, 2004;34:958–64.


106. Maiti R, Rahman J, Jaida J, et al., Rupatadine and levocetirizine for seasonal allergic rhinitis: a comparative study of efficacy and safety, Arch Otolaryngol Head Neck Surg, 2010;136:796–800.


107. Valero A, Izquierdo I, Giralt J, et al., Rupatadine Improves Nasal Symptoms, Quality of Life (ESPRINT-15), and Severity in a Subanalysis of a Cohort of Spanish Allergic Rhinitis Patients, J Investig Allergol Clin Immunol, 2011;21:229–35.


108. ESPRINT Study Group and Investigators, Development and validation of a new Spanish instrument to measure health- related quality of life in patients with allergic rhinitis: the ESPRINT questionnaire, Value Health, 2007;10(6):466–7.


109. Valero A, Alonso J, Antépara I, et al., Health-related quality of life in allergic rhinitis: comparing the short form ESPRINT-15 and MiniRQLQ questionnaires, Allergy, 2007;62(12):1372–8.


110. Costa DJ, Amouyal M, Lambert P, et al., How representative are clinical study patients with allergic rhinitis in primary care?, J Allergy Clin Immunol, 2011;127:920–6.


111. Shedden A, impact of nasal congestion on quality of life and work productivity in allergic rhinitis: findings from a large online survey, Treat Respir Med, 2005;4(6):439–46.


EUROPEAN RESPIRATORY DISEASE


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76